DIN EN ISO 10993-11:2018-09 (E)

Biological evaluation of medical devices - Part 11: Tests for systemic toxicity (ISO 10993-11:2017)

Contents

Page

European foreword ... **4**

Endorsement notice ... **5**

Annex ZA (informative) **Relationship between this European Standard and the essential requirements of Directive 93/42/EEC [OJ L 169] aimed to be covered** ... **6**

Annex ZB (informative) **Relationship between this European Standard and the essential requirements of Directive 90/385/EEC [OJ L 189] aimed to be covered** ... **8**

Foreword ... **10**

Introduction ... **11**

1 Scope ... **12**

2 Normative references ... **12**

3 Terms and definitions ... **12**

4 General considerations ... **14**
4.1 General ... 14
4.2 Selection of animal species ... 14
4.3 Animal status ... 14
4.4 Animal care and husbandry ... 14
4.5 Size and number of groups ... 15
4.5.1 Size of groups ... 15
4.5.2 Number of groups ... 15
4.5.3 Treatment controls ... 15
4.6 Route of exposure ... 16
4.7 Sample preparation ... 16
4.8 Dosing ... 16
4.8.1 Test sample administration ... 16
4.8.2 Dosage volumes ... 16
4.8.3 Dosage frequency ... 17
4.9 Body weight and food/water consumption ... 17
4.10 Clinical observations ... 17
4.11 Clinical pathology ... 17
4.12 Anatomic pathology ... 18
4.13 Study designs ... 18
4.14 Quality of investigation ... 18

5 Acute systemic toxicity ... **18**
5.1 General ... 18
5.2 Study design ... 19
5.2.1 Preparations ... 19
5.2.2 Experimental animals ... 19
5.2.3 Test conditions ... 19
5.2.4 Body weights ... 20
5.2.5 Clinical observations ... 20
5.2.6 Pathology ... 20
5.3 Evaluation criteria ... 21
5.3.1 General ... 21
5.3.2 Evaluation of results ... 21
5.4 Final report ... 21

6 Repeated exposure systemic toxicity (subacute, subchronic and chronic systemic toxicity) **23**
6.1 General 23
6.2 Study design 23
6.2.1 Preparations 23
6.2.2 Experimental animals 23
6.2.3 Test conditions 24
6.2.4 Body weights 24
6.2.5 Clinical observations 24
6.2.6 Pathology 24
6.3 Evaluation criteria 25
6.3.1 General 25
6.3.2 Evaluation of results 25
6.4 Final report 26
Annex A (informative) **Routes of administration** **27**
Annex B (informative) **Dosage volumes** **29**
Annex C (informative) **Common clinical signs and observations** **30**
Annex D (informative) **Suggested haematology, clinical chemistry and urinalysis measurements** **31**
Annex E (informative) **Suggested organ list for histopathological evaluation** **33**
Annex F (informative) **Organ list for limited histopathology for medical devices subjected to systemic toxicity testing** **35**
Annex G (informative) **Information on material-mediated pyrogens** **36**
Annex H (informative) **Subchronic rat — Dual routes of parenteral administration** **37**
Bibliography **39**